Stock Analiz

DataMeds AI, Inc. MEDS

Other Pharmaceuticals · IPO 2025 · data as of November 13, 2026

$0.74Market cap $4M
Open the interactive analysis →

DataMeds AI, Inc. (MEDS) is a healthcare company listed in the US with a market value of about $4M. In the twelve months to September 30, 2026 it had revenue of $8M and net income of -$43M, a net margin of -564.8%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -311%.

About DataMeds AI

DataMeds AI is listed in the US and classified in other pharmaceuticals, IPO year 2025. It was profitable in 0 of the last 3 years in our data.

Score: 0.6 / 5

Value0/5
Future growth2/5
Track record1/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • Strong R&D investment or growth above 20%
  • ROE above 15%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.5
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-432.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)28.7%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-235.9%
ROIC (5-yr avg.)-311.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 3 years

Fiscal yearTTM202520242023
Revenue$8M$23M$18M—
Net income-$43M-$101M-$7M-$3M
Free cash flow-$16M-$11M-$1M-$349136
EPS (diluted)$-9.16$-21.45$-2.25$-0.90
Net margin-564.8%-433.9%-37.8%—
ROIC—-606.8%-15.2%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does DataMeds AI pay a dividend?

Not currently.

Is DataMeds AI a good stock to buy?

We do not give buy or sell advice. DataMeds AI scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.